LONDON (Reuters) -GSK CEO Emma Walmsley gave an upbeat assessment of the British drugmaker's new respiratory syncytial virus (RSV) vaccine on Thursday and said the costs of Zantac litigation won't ...

GSK shares have lagged rivals in recent years*Zantac litigation 'clear overhang' on stock-CEO*Walmsley defends GSK's work on drug pipeline*RSV vaccine data for U.S. for 50-59 year olds by year-end-CEO ...

Emma Walmsley, the Chief Executive Officer of GSK plc (NYSE: GSK), expressed confidence in its respiratory syncytial virus (RSV) vaccine, Arexvy, anticipating sales to surpass £1 billion ($1.26 ...

United States health authorities Monday gave full approval to the COVID-19 vaccine developed by Pfizer-BioNTech ... The Food and Drug Administration's (FDA) decision emergency use authorization ...

The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of ...

While there is no maternal RSV vaccine available in the United States, GSK Plc earlier this month became the first to secure US approval of an RSV shot for older adults. The FDA is expected to decide ...

The FDA just approved this vaccine back in May after years of research leading up to it. The CDC said RSV is the leading ...

As RSV cases increase, doctors at CHI Health are encouraging people most at risk to take precautions. This includes getting ...

Of the roughly 14,000 doses requested by CT, only about 10,000 have been received and distributed, CT public health officials ...

"Pfizer is deeply committed to the well-being of the patients it serves and has no higher priority than the safety and ...